Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novavax’s Q4 losses surge
For the year ended December 31, 2007, the company reported a net loss of $34.8 million ($0.57 loss per share) compared to a net loss of $23.1 million
For the year ended December 31, 2007, the company reported a net loss of $34.8 million ($0.57 loss per share) compared to a net loss of $23.1 million
For the fiscal year ended December 31, 2007, the company reported a net loss of $25 million, or $0.31 per share, compared to a net loss of $18
For the full year, Cytogen reported a net loss of $25.7 million, or $0.79 per diluted share in 2007, compared to a net loss of $15.1 million, or
Under the terms of the settlement, the pending action will be dismissed with prejudice and without any admission of liability on the part of the company or any
The trial is designed to evaluate the safety and efficacy of ARC1779 as a first-in-class anti-platelet agent in patients suffering from life-threatening blood disorder known as thrombotic thrombocytopenic
BioMerieux and Hitachi High-Technologies will work together to identify and develop new systems. The new instruments developed under this partnership will be manufactured by Hitachi High-Technologies and distributed
The interim analysis demonstrated statistically significant efficacy for the patient group receiving 500mg b.i.d. of vernakalant (oral) as compared to placebo. The safety data from the interim analysis
This biologics license application (BLA) submission by Ipsen is intended to address the concerns cited by the FDA when it declined to file the Reloxin BLA in January
Deals have been brokered with three international distributors to date – Pacific Medical, which will target select countries in Asia; Sanitas covering Turkey; and the Golden Triangle Organization,
The pilot program included 100 participants (50 in the PTP group and 50 in a control group). Patients were evaluated for program participation eligibility by Community Bridges treatment